Abstract 225P
Background
Prostate cancer ranges from indolent to aggressive, with 10–20% of patients developing metastases. Immune cell interactions in the tumor microenvironment facilitate growth. This study aimed to characterize circulating immune cells in patients with oligometastatic (OMPC) and plurimetastatic prostate cancer (PMPC).
Methods
This retrospective cohort study included individuals with metastatic prostate cancer (mPC). Patients were classified into two groups: OMPC (five or fewer lesions in bone and/or lymph nodes via CT or bone scans), and PMPC, those not meeting OMPC criteria. Demographic data and immune cell subsets were collected at admission. After blood collection, peripheral blood mononuclear cells were isolated, and flow cytometry assessed various immune populations (γδ T cells, αβ T cells, Tregs, memory T cells, effector T cells, NK cells, NKT cells, B cells, myeloid cells, and monocytes) and cytokines (TNF-α, IFN-γ, IL-17). The Mann–Whitney U test was used for comparisons, with p ≤ 0.05 considered significant.
Results
43 patients were identified, with a median age of 64 years (50-80). 17 patients (39.5%) had OMPC and 26 (60.5%) had PMPC. 16 patients (37.2%) presented with de novo mPC. Bone was the most common metastatic site in both groups. Most patients (67.4%, n=29) received hormone therapy (HT) as first-line treatment , while 9 patients (20.9%) received chemotherapy plus HT. An increase in γδ2+ T cells (p=0.048) was noted in the OMPC group. There was a trend toward increased levels of γδ2+ expressing IFN-γ (p=0.066) in PMPC patients.
Conclusions
A significant increase in γδ2+ T cells was observed in OMPC. These cells are critical for immune modulation. Elevated levels in OMPC subgroup may indicate an active immune response, potentially providing a protective effect against tumor progression in this subgroup. Conversely, PMPC patients showed a trend toward increased IFN-γ expression in γδ2+ T cells (p=0.066). While these cells can produce IFN-γ, those in OMPC may be less activated, limiting their effectiveness and suggesting an immune escape mechanism. This study has limitations; results are exploratory and require confirmation in a larger cohort. We plan to validate the differences in γδ2+ T cells and IFN-γ expression in an independent group.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session